These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16416302)

  • 21. Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals.
    Usmani KA; Rose RL; Hodgson E
    Drug Metab Dispos; 2003 Apr; 31(4):384-91. PubMed ID: 12642463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
    Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
    Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone.
    Di Marco A; Marcucci I; Verdirame M; Pérez J; Sanchez M; Peláez F; Chaudhary A; Laufer R
    Drug Metab Dispos; 2005 Mar; 33(3):349-58. PubMed ID: 15608130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam.
    Tang J; Amin Usmani K; Hodgson E; Rose RL
    Chem Biol Interact; 2004 Apr; 147(3):319-29. PubMed ID: 15135087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
    Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
    Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
    Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.
    Kajita J; Kuwabara T; Kobayashi H; Kobayashi S
    Drug Metab Dispos; 2000 Sep; 28(9):1121-7. PubMed ID: 10950859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
    Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
    Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH; Jones DR; Hall SD
    Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
    Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
    Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
    Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
    Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
    Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
    Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
    Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
    Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes.
    Draper AJ; Madan A; Smith K; Parkinson A
    Drug Metab Dispos; 1998 Apr; 26(4):299-304. PubMed ID: 9531515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.
    Wang RW; Newton DJ; Scheri TD; Lu AY
    Drug Metab Dispos; 1997 Apr; 25(4):502-7. PubMed ID: 9107550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
    J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
    Polasek TM; Elliot DJ; Lewis BC; Miners JO
    J Pharmacol Exp Ther; 2004 Dec; 311(3):996-1007. PubMed ID: 15304522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
    Galetin A; Clarke SE; Houston JB
    Drug Metab Dispos; 2003 Sep; 31(9):1108-16. PubMed ID: 12920166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic drug interactions of macrolides.
    Periti P; Mazzei T; Mini E; Novelli A
    Clin Pharmacokinet; 1992 Aug; 23(2):106-31. PubMed ID: 1511528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.